Filing Flows › NRX Pharmaceuticals (NRXP) › Q1 2026
NRX Pharmaceuticals (NRXP) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
NRX Pharmaceuticals (NRXP) reported revenue of $1.1M for the first quarter 2026 (Q1 2026) and -11% from the quarter before. Operating margin was -444.0%, net loss $1.4M (133.9% of revenue).
NRX Pharmaceuticals, Q1 2026: revenue $1.1M, operating margin -444.0%, net loss $1.4M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -11% | — |
| Operating profit | −$4.7M | — | — |
| Net earnings | −$1.4M | -497% | — |
| Operating cash flow | −$4.3M | — | — |
What changed
Revenue was $1.1M in Q1 2026, down 11% from the previous quarter. Therapy was the largest line at 71% of revenue.
Operating costs exceeded revenue by $4.7M, an operating margin of -444.0%. The quarter ended with a net loss of $1.4M, after a profit of $360K the previous quarter. Non-operating items added $3.3M, -232% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.3M. Non-cash charges added back $63K of depreciation and amortization and $151K of share-based compensation. Working capital and other items used $3.1M.
Questions
What was NRX Pharmaceuticals' revenue in the first quarter 2026?
NRX Pharmaceuticals (NRXP) reported revenue of $1.1M for the first quarter 2026 (Q1 2026) and -11% from the quarter before.
Was NRX Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $4.7M (-444.0% of revenue) and net loss $1.4M.